注册 | 登录
点击这里给我发消息
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   发育生物学   >   Fagilis (IFITM3) Antibody (Center)   

Fagilis (IFITM3) Antibody (Center)

Purified Rabbit Polyclonal Antibody (Pab)

     
  • 1 - Fagilis (IFITM3) Antibody (Center) AP1153c
    Western blot analysis of IFITM3 (arrow) using rabbit polyclonal IFITM3 Antibody (C-term) (Cat# AP1153c).293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the IFITM3 gene (Lane 2) (Origene Technologies).
  • 1 - Fagilis (IFITM3) Antibody (Center) AP1153c
    Western blot analysis of anti-IFITM3 Antibody (Center) (Cat# AP1153c) in Hela cell line lysates (35ug/lane). IFITM3(arrow) was detected using the purified Pab.
  • 产品详情
  • 文献引用 : 1
  • 实验流程
  • 背景知识
Product Information
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
WB, E
Primary Accession Q01628
Other Accession Q9CQW9, Q99J93, Q01629, P13164
Reactivity Human
Predicted Mouse
Host Rabbit
Clonality Polyclonal
Isotype Rabbit IgG
Calculated MW 14632 Da
Antigen Region 64-93 aa
Additional Information
Gene ID 10410
Other Names Interferon-induced transmembrane protein 3, Dispanin subfamily A member 2b, DSPA2b, Interferon-inducible protein 1-8U, IFITM3
Target/Specificity This Fagilis (IFITM3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 64-93 amino acids from the Central region of human Fagilis (IFITM3).
Dilution WB~~1:1000
E~~Use at an assay dependent concentration.
Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
StorageMaintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
PrecautionsFagilis (IFITM3) Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.
Protein Information
Name IFITM3 (HGNC:5414)
Function IFN-induced antiviral protein which disrupts intracellular cholesterol homeostasis. Inhibits the entry of viruses to the host cell cytoplasm by preventing viral fusion with cholesterol depleted endosomes. May inactivate new enveloped viruses which buds out of the infected cell, by letting them go out with a cholesterol depleted membrane. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:26354436, PubMed:33239446, PubMed:33270927). Can inhibit: influenza virus hemagglutinin protein- mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS- CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein- mediated viral entry (PubMed:33270927). Plays a critical role in the structural stability and function of vacuolar ATPase (v-ATPase). Establishes physical contact with the v-ATPase of endosomes which is critical for proper clathrin localization and is also required for the function of the v-ATPase to lower the pH in phagocytic endosomes thus establishing an antiviral state. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436). Exerts opposing activities on SARS-CoV-2, including amphipathicity-dependent restriction of virus at endosomes and amphipathicity-independent enhancement of infection at the plasma membrane (PubMed:33270927).
Cellular Location Cell membrane; Single-pass type II membrane protein. Late endosome membrane; Single-pass type II membrane protein. Early endosome membrane; Single-pass type II membrane protein Lysosome membrane; Single-pass type II membrane protein. Cytoplasm, perinuclear region. Note=Co-localizes with BRI3 isoform 1 at the perinuclear region.
Research Areas

For Research Use Only. Not For Use In Diagnostic Procedures.

BACKGROUND

The family of interferon-induced transmembrane protein (Ifitm/mil/fragilis) cell surface proteins may modulate cell adhesion and influence cell differentiation.

REFERENCES

Tanaka,S.S., Dev. Cell 9 (6), 745-756 (2005)

FeedBack

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-88856768 tech-china@abcepta.com.


我要评价